ImpactRx acquires AlphaDetail

AlphaDetail becomes ImpactRx’s custom market research unit. ImpactRx president and CEO Gregory Ellis (pictured) said: “AlphaDetail’s deep understanding of client needs and exceptional analytical talent will enable ImpactRx to provide incremental value to our clients.

“For example, clients’ product forecasting needs will be better served by integrating AlphaDetail’s trusted ability to develop and conduct actionable research with ImpactRx’s data assets and capabilities.”

ImpactRx maintains panels of physicians to monitor the effect that product promotions have on their prescribing behaviour. Last year it merged with rival TargetRx, six months after being bought by Symphony Technology Group.